The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10359982" target="_blank" >RIV/00216208:11140/17:10359982 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/17:10359982 RIV/00023884:_____/12:00007534
Result on the web
<a href="http://iv.iiarjournals.org/content/31/3/303.long" target="_blank" >http://iv.iiarjournals.org/content/31/3/303.long</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.11059" target="_blank" >10.21873/invivo.11059</a>
Alternative languages
Result language
angličtina
Original language name
The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice
Original language description
Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF), especially its pegylated forms, significantly reduces the incidence of FN, the likelihood of chemotherapy dose intensity reduction and, also, the number of hospitalizations due to FN. This review discusses currently published results from clinical trials dealing with FN prophylaxis in routine clinical practice in patients with solid tumors and myeloproliferative malignancies with a focus on lipegfilgrastim, which is the newest modification of the original molecule filgrastim. The discussed results proved that prophylactic administration of lipegfilgrastim can almost eliminate the risk of FN and significantly reduce the risk of chemotherapy (CHT) dose reduction in routine clinical practice in cases of a clear highrisk chemotherapy regimen or in the presence of risk factors (such as age, comorbidities, performance status, etc.) in patients who received chemotherapy with medium risk of FN.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
In Vivo
ISSN
0258-851X
e-ISSN
—
Volume of the periodical
31
Issue of the periodical within the volume
3
Country of publishing house
GR - GREECE
Number of pages
4
Pages from-to
303-306
UT code for WoS article
000400046000004
EID of the result in the Scopus database
2-s2.0-85018720976